Patents by Inventor Megumi Numata

Megumi Numata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of administering anti-IL31A antibody-containing formulations
    Patent number: 11723976
    Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: August 15, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
  • ANTI-IL-31RA ANTIBODY-CONTAINING FORMULATIONS
    Publication number: 20220184210
    Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
  • ANTIBODY-CONTAINING FORMULATIONS
    Publication number: 20220125921
    Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.
    Type: Application
    Filed: January 12, 2022
    Publication date: April 28, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
  • Anti-IL31RA antibody-containing formulations
    Patent number: 11260125
    Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: March 1, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
  • ANTIBODY-CONTAINING FORMULATIONS
    Publication number: 20210322550
    Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.
    Type: Application
    Filed: June 14, 2021
    Publication date: October 21, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa